Sarepta Therapeutics Announces Favorable Safety Results from Phase I Clinical Study of Influenza Drug Candidate

September 30, 2014 Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today announced favorable safety results from the single ascending dose portion of a Phase I study of AVI-7100, the company’s lead candidate for the treatment of influenza virus, in healthy volunteers. The clinical trial is being conducted at the National Institutes of Health (NIH) through a collaboration between …

Harrisvaccines Becomes First In The Nation To Receive USDA Conditional License For PEDv Vaccine

June 16, 2014 Ames, Iowa-based vaccine producer, Harrisvaccines, today announced it has been granted United States Department of Agriculture (USDA) conditional licensure of the company’s Porcine Epidemic Diarrhea Virus (PEDv) Vaccine, RNA utilizing its SirraVaxSM RNA Particle Technology. This is the first USDA conditional license granted for a PEDv vaccine since the initial outbreak, and it will allow Harrisvaccines to sell their vaccine directly …